(HealthDay)—Regular use of fluticasone furoate (FF), either alone or in combination with vilanterol (VI), appears to reduce the rate of forced expiratory volume in one second (FEV1) decline in patients with moderate chronic obstructive pulmonary disease (COPD) and a high risk of cardiovascular disease, according to a study published online July 24 in the American Journal...